ALBUQUERQUE, N.M., Sept. 14, 2009 (GLOBE NEWSWIRE) -- Biomoda, Inc.'s (OTCBB:BMOD) (www.biomoda.com) Phase II clinical trial to screen military veterans for early-stage lung cancer has been enhanced to include a longitudinal component, which will provide additional data on the efficacy of the Biomoda diagnostic.
